Rusfertide vs Tesamorelin
Overview
Rusfertide is primarily a weight management & metabolic peptide, while Tesamorelin is used for performance & growth.
This page compares Rusfertide and Tesamorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Rusfertide | Tesamorelin | |
|---|---|---|
| Category | Weight Management & Metabolic | Performance & Growth |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 19-108 mg | 2 mg |
| Frequency | once weekly, subcutaneous | daily |
| Reported benefits | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. | Visceral fat reduction, improved body composition, GH release |
| Reported side effects | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. | Joint pain, peripheral edema |
Key differences
Primary use. Rusfertide is categorised under Weight Management & Metabolic, while Tesamorelin falls under Performance & Growth. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Rusfertide: FDA-approved. Tesamorelin: FDA-approved.
Dosing. Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous). Tesamorelin is typically dosed at 2 mg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Rusfertide and Tesamorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Rusfertide and Tesamorelin?
- Rusfertide is primarily a weight management & metabolic peptide, while Tesamorelin is used for performance & growth. Rusfertide is FDA-approved for one or more indications, whereas Tesamorelin is FDA-approved for one or more indications.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- What is Tesamorelin used for?
- GHRH for visceral fat.
- Can you take Rusfertide and Tesamorelin together?
- Some users combine peptides within a single protocol, but stacking Rusfertide and Tesamorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Rusfertide or Tesamorelin FDA-approved?
- Rusfertide is FDA-approved for one or more indications. Tesamorelin is FDA-approved for one or more indications.
Read the full articles
- Rusfertide — full monograph: mechanism, research, dosing & references
- Tesamorelin — full monograph: mechanism, research, dosing & references